|
Table 2. Recommended pan-genotypic treatment protocols for people with hepatitis C virus (HCV) infection and compensated liver disease, including people with HCV–HIV coinfection*
|
|
Regimen
|
HCV genotype
|
Pill burden
|
Treatment duration
|
|
No cirrhosis
|
Cirrhosis
|
|
First-line regimens for people who are treatment-naive
|
|
Sofosbuvir 400 mg, orally, daily
+
Velpatasvir 100 mg, orally, daily
|
1–6
|
1 pill daily
|
12 weeks
|
12 weeks
|
|
Glecaprevir 300 mg, orally, daily
+
Pibrentasvir 120 mg, orally, daily
|
1–6
|
Once daily (3 pills)
|
8 weeks
|
8 weeks*
|
|
Regimen for people who do not respond to first-line therapy due to virological failure
|
|
Sofosbuvir 400 mg, orally, daily
+
Velpatasvir 100 mg, orally, daily
+
Voxilaprevir 100 mg, orally, daily
|
1–6
|
1 pill daily
|
12 weeks
|
12 weeks
|
|
HIV = human immunodeficiency virus.
* A treatment duration of 12 weeks may be considered for patients with compensated cirrhosis, at the discretion of the prescriber.
|
